Clinical trial design

UK
#Clinical trial design #Clinical trials #National Institute for Health and Care Research #UK

UK clinical trial set-up times drop significantly

Efforts by the National Institute for Health and Care Research (NIHR) have led to a fall in clinical research study set-up times, new UK government figures have revealed.  Data show that the time taken to set up commercial interventional clinical trials in the UK has fallen significantly,… Read More

#News

Doctor holding x-ray
#Clinical trial design #Clinical trials #Oncology #Osteosarcoma #Paediatrics

Novel regulatory science considerations in osteosarcoma: the imperative for regulatory flexibility to meet critical unmet patient and clinical needs

Introduction Rare diseases, as classified by the FDA and EMA, are conditions that affect fewer than 200,00 people in the US1 or fewer than five in 10,000 people in the EU2. Because of these small populations, rare diseases often face unique – and some respects potentially more significant – hurdles… Read More

#Exclusive Content

FDA headquarters
#Clinical trial design #Clinical trials #FDA #Real-time clinical trials

FDA moves towards real-time clinical trials

The US Food and Drug Administration has announced two major steps as part of an initiative to advance the implementation of real-time clinical trials (RTCT).   First, the agency unveiled the successful initiation of two proof-of-concept clinical trials that will report endpoints and data signals to the agency in real time. Read More

#Editor's Choice #News #Regulatory #Trending News

#ABPI #Clinical trial design #Clinical trials #Real world data

NHS health data should be used for clinical trial recruitment, says ABPI

The UK has an opportunity to enhance its global competitiveness in the delivery of industry clinical trials by harnessing NHS health data to more efficiently recruit patients, according to a new report from the ABPI.  Following a period of decline, the number of industry clinical trials in… Read More

#News

Laboratory research
#Clinical trial design #Clinical trials #Medical Research Council #National Institute for Health and Care Excellence (NICE)

£50m UK centre to overhaul clinical trial design

A new UK initiative aims to shake-up approaches to clinical trial design and delivery by developing new ways to speed up the process and drive improvements.  The Medical Research Council Centre of Research Excellence in Clinical Trial Innovation in partnership with the National Institute for Health and… Read More

#News

#Clinical trial design #Clinical trials #Rare disease

Clinical trials in rare and life-limiting diseases

Dr Tony Lockett, Chief Medical Officer at Nevrargenics, explores the future of clinical trials in rare diseases. Clinical trials are in crisis. Over 80% of clinical trials over-run in costs and time and 60% of trials also do not make their endpoint. In this circumstance, it is hardly surprising that… Read More

#Exclusive Content

#Artificial intelligence (AI) #Clinical trial design #Clinical trials #Drug discovery

The next generation of clinical trials with AI

Niven R Narain, President and CEO, BPGbio, looks at how biology-first Bayesian causal AI is redefining success in drug development. From using AI-based computational modelling to phase out animal testing for monoclonal antibodies1, to deploying its proprietary large language model-powered tool, Elsa, to read, write, and summarise regulatory documents—reducing review time… Read More

#Exclusive Content

Artificial intelligence
#AI / data analytics / healthtech / informatics #Antibodies #Antibody-based therapeutics #Artificial intelligence (AI) #Clinical trial design #Clinical trials #Start-ups

New podcast: Innovative applications of AI in drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovative applications of AI in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Decoding diseases: The AI renaissance in clinical trials” and “Advancing antibody… Read More

#News

HIV cell
#Clinical trial design #Gilead Sciences #HIV #Phase III trial

Yeztugo provides strong HIV protection in diverse patient groups

Gilead Sciences will share new Phase III trial data showing that twice-yearly lenacapavir (Yeztugo) was effective and well tolerated among a broad range of populations who need or want pre-exposure prophylaxis (PrEP) for HIV prevention.  The new data, from the company’s pivotal Phase III PURPOSE 1 and… Read More

#News

#Artificial intelligence (AI) #Clinical trial design #Drug discovery #Lab technology #SLAS

New DDW Highlights podcast: 30 June 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we announce the DDW ‘Creating cures’ programme at SLAS2026, the week’s news highlights emphasise… Read More

#News

#Artificial intelligence (AI) #Clinical trial design #Drug discovery #Lab technology #SLAS

This week in drug discovery (23-27 June) 

News round-up for 23-27 June by DDW Senior Digital Content Editor Diana Spencer. As we announce the DDW ‘Creating cures’ programme at SLAS2026, the week’s news highlights emphasise the importance of advanced technologies to the success of drug discovery, including digital control arms for clinical studies, nanobody-based… Read More

#News

#Artificial intelligence (AI) #Clinical trial design #Deep learning #Fibrosis #Imaging #Interview

How is deep learning imaging advancing drug discovery for fibrosis?

Diana Spencer speaks to Dr Muhunthan Thillai, CEO at Qureight, about the company’s AI-powered imaging analytics and the technology’s potential in lung diseases and beyond.  DS: Can you provide some background to the company? MT: We are a core imaging laboratory using deep-learning and analytics to advance clinical trials and… Read More

#Exclusive Content

#Artificial intelligence (AI) #Clinical trial design #Clinical trials #European Medicines Agency #Liver disease

EMA qualifies first AI tool to diagnose liver disease in trials

The European Medicine Agency’s (EMA’s) human medicines committee (CHMP) has issued the first Qualification Opinion (QO) on a development methodology based on artificial intelligence (AI).   The tool, called AIM-NASH, helps pathologists analyse liver biopsy scans to identify the severity of MASH (metabolic dysfunction associated steatohepatitis; formerly known… Read More

#News

#Clinical trial design #Clinical trials #Drug development #Drug discovery

New DDW Highlights podcast: 17 March 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Clinical trials of all stages have dominated the DDW news section this week. All… Read More

#News

#Clinical trial design #Clinical trials #Drug development #Drug discovery

This week in drug discovery (10-14 March) 

News round-up for 10-14 March by DDW Senior Digital Content Editor Diana Spencer. Clinical trials of all stages have dominated the DDW news section this week. All the stories represent a significant step forward for drug discovery, either due to the innovative nature of the therapies being studied,… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical trial #Clinical trial design #Phesi

Over collection of data delays clinical trials, report finds

A significant number of Phase III clinical trials are over-collecting data because of overcomplicated protocol designs, leading to avoidable delays in drug development times, says a new report.  Phesi used proprietary data from its Trial Accelerator Platform to analyse 2,401 industry-sponsored Phase III clinical trials that have… Read More

#News